Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
Fiche publication
Date publication
juillet 2020
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe, Pr PETIT Thierry
Tous les auteurs :
Heudel P, Delaloge S, Parent D, Madranges N, Levy C, Dalenc F, Brain E, Uwer L, D'Hondt V, Augereau P, Mailliez A, Perrin C, Frenel JS, Sablin MP, Mouret-Reynier MA, Vermeulin T, Eymard JC, Petit T, Ferrero JM, Ilie S, Goncalves A, Chenuc G, Robain M, Simon G, Perol D
Lien Pubmed
Résumé
Vinorelbine is indicated for use in the treatment of MBC as a single agent or in combination but there is little real world data on this molecule and even less on its oral form. We exploited the Unicancer Epidemiology Strategy Medical-Economics (ESME) metastatic breast cancer (MBC) database to investigate current patterns of use of oral vinorelbine (OV), as well as outcomes of patients receiving this drug.
Mots clés
ESME, Vinorelbine, metastatic breast cancer, real-world data, retrospective study
Référence
Anticancer Res.. 2020 Jul;40(7):3905-3913